Role of Nrf2 and Autophagy in Acute Lung Injury

Montserrat Rojo de la Vega, Matthew Dodson, Christine Gross, Heidi M. Mansour, R. Clark Lantz, Eli Chapman, Ting Wang, Stephen Matthew Black, Joe G.N. Garcia, Donna D. Zhang

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the clinical manifestations of severe lung damage and respiratory failure. Characterized by severe inflammation and compromised lung function, ALI/ARDS result in very high mortality of affected individuals. Currently, there are no effective treatments for ALI/ARDS, and ironically, therapies intended to aid patients (specifically mechanical ventilation, MV) may aggravate the symptoms. Key events contributing to the development of ALI/ARDS are increased oxidative and proteotoxic stresses, unresolved inflammation, and compromised alveolar-capillary barrier function. Since the airways and lung tissues are constantly exposed to gaseous oxygen and airborne toxicants, the bronchial and alveolar epithelial cells are under higher oxidative stress than other tissues. Cellular protection against oxidative stress and xenobiotics is mainly conferred by Nrf2, a transcription factor that promotes the expression of genes that regulate oxidative stress, xenobiotic metabolism and excretion, inflammation, apoptosis, autophagy, and cellular bioenergetics. Numerous studies have demonstrated the importance of Nrf2 activation in the protection against ALI/ARDS, as pharmacological activation of Nrf2 prevents the occurrence or mitigates the severity of ALI/ARDS. Another promising new therapeutic strategy in the prevention and treatment of ALI/ARDS is the activation of autophagy, a bulk protein and organelle degradation pathway. In this review, we will discuss the strategy of concerted activation of Nrf2 and autophagy as a preventive and therapeutic intervention to ameliorate ALI/ARDS.

Original languageEnglish (US)
Pages (from-to)91-101
Number of pages11
JournalCurrent Pharmacology Reports
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Acute Lung Injury
Adult Respiratory Distress Syndrome
Autophagy
Oxidative stress
Chemical activation
Xenobiotics
Oxidative Stress
Tissue
Metabolism
Transcription Factors
Genes
Apoptosis
Oxygen
Inflammation
Alveolar Epithelial Cells
Therapeutics
Degradation
Lung
Artificial Respiration
Respiratory Insufficiency

Keywords

  • Acute lung injury
  • Autophagy
  • Nrf2
  • Oxidative stress

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

de la Vega, M. R., Dodson, M., Gross, C., Mansour, H. M., Lantz, R. C., Chapman, E., ... Zhang, D. D. (2016). Role of Nrf2 and Autophagy in Acute Lung Injury. Current Pharmacology Reports, 2(2), 91-101. https://doi.org/10.1007/s40495-016-0053-2

Role of Nrf2 and Autophagy in Acute Lung Injury. / de la Vega, Montserrat Rojo; Dodson, Matthew; Gross, Christine; Mansour, Heidi M.; Lantz, R. Clark; Chapman, Eli; Wang, Ting; Black, Stephen Matthew; Garcia, Joe G.N.; Zhang, Donna D.

In: Current Pharmacology Reports, Vol. 2, No. 2, 01.04.2016, p. 91-101.

Research output: Contribution to journalReview article

de la Vega, MR, Dodson, M, Gross, C, Mansour, HM, Lantz, RC, Chapman, E, Wang, T, Black, SM, Garcia, JGN & Zhang, DD 2016, 'Role of Nrf2 and Autophagy in Acute Lung Injury', Current Pharmacology Reports, vol. 2, no. 2, pp. 91-101. https://doi.org/10.1007/s40495-016-0053-2
de la Vega MR, Dodson M, Gross C, Mansour HM, Lantz RC, Chapman E et al. Role of Nrf2 and Autophagy in Acute Lung Injury. Current Pharmacology Reports. 2016 Apr 1;2(2):91-101. https://doi.org/10.1007/s40495-016-0053-2
de la Vega, Montserrat Rojo ; Dodson, Matthew ; Gross, Christine ; Mansour, Heidi M. ; Lantz, R. Clark ; Chapman, Eli ; Wang, Ting ; Black, Stephen Matthew ; Garcia, Joe G.N. ; Zhang, Donna D. / Role of Nrf2 and Autophagy in Acute Lung Injury. In: Current Pharmacology Reports. 2016 ; Vol. 2, No. 2. pp. 91-101.
@article{d610943f00be4f8190a7779a5b444f84,
title = "Role of Nrf2 and Autophagy in Acute Lung Injury",
abstract = "Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the clinical manifestations of severe lung damage and respiratory failure. Characterized by severe inflammation and compromised lung function, ALI/ARDS result in very high mortality of affected individuals. Currently, there are no effective treatments for ALI/ARDS, and ironically, therapies intended to aid patients (specifically mechanical ventilation, MV) may aggravate the symptoms. Key events contributing to the development of ALI/ARDS are increased oxidative and proteotoxic stresses, unresolved inflammation, and compromised alveolar-capillary barrier function. Since the airways and lung tissues are constantly exposed to gaseous oxygen and airborne toxicants, the bronchial and alveolar epithelial cells are under higher oxidative stress than other tissues. Cellular protection against oxidative stress and xenobiotics is mainly conferred by Nrf2, a transcription factor that promotes the expression of genes that regulate oxidative stress, xenobiotic metabolism and excretion, inflammation, apoptosis, autophagy, and cellular bioenergetics. Numerous studies have demonstrated the importance of Nrf2 activation in the protection against ALI/ARDS, as pharmacological activation of Nrf2 prevents the occurrence or mitigates the severity of ALI/ARDS. Another promising new therapeutic strategy in the prevention and treatment of ALI/ARDS is the activation of autophagy, a bulk protein and organelle degradation pathway. In this review, we will discuss the strategy of concerted activation of Nrf2 and autophagy as a preventive and therapeutic intervention to ameliorate ALI/ARDS.",
keywords = "Acute lung injury, Autophagy, Nrf2, Oxidative stress",
author = "{de la Vega}, {Montserrat Rojo} and Matthew Dodson and Christine Gross and Mansour, {Heidi M.} and Lantz, {R. Clark} and Eli Chapman and Ting Wang and Black, {Stephen Matthew} and Garcia, {Joe G.N.} and Zhang, {Donna D.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s40495-016-0053-2",
language = "English (US)",
volume = "2",
pages = "91--101",
journal = "Current Pharmacology Reports",
issn = "2198-641X",
publisher = "Springer International Publishing AG",
number = "2",

}

TY - JOUR

T1 - Role of Nrf2 and Autophagy in Acute Lung Injury

AU - de la Vega, Montserrat Rojo

AU - Dodson, Matthew

AU - Gross, Christine

AU - Mansour, Heidi M.

AU - Lantz, R. Clark

AU - Chapman, Eli

AU - Wang, Ting

AU - Black, Stephen Matthew

AU - Garcia, Joe G.N.

AU - Zhang, Donna D.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the clinical manifestations of severe lung damage and respiratory failure. Characterized by severe inflammation and compromised lung function, ALI/ARDS result in very high mortality of affected individuals. Currently, there are no effective treatments for ALI/ARDS, and ironically, therapies intended to aid patients (specifically mechanical ventilation, MV) may aggravate the symptoms. Key events contributing to the development of ALI/ARDS are increased oxidative and proteotoxic stresses, unresolved inflammation, and compromised alveolar-capillary barrier function. Since the airways and lung tissues are constantly exposed to gaseous oxygen and airborne toxicants, the bronchial and alveolar epithelial cells are under higher oxidative stress than other tissues. Cellular protection against oxidative stress and xenobiotics is mainly conferred by Nrf2, a transcription factor that promotes the expression of genes that regulate oxidative stress, xenobiotic metabolism and excretion, inflammation, apoptosis, autophagy, and cellular bioenergetics. Numerous studies have demonstrated the importance of Nrf2 activation in the protection against ALI/ARDS, as pharmacological activation of Nrf2 prevents the occurrence or mitigates the severity of ALI/ARDS. Another promising new therapeutic strategy in the prevention and treatment of ALI/ARDS is the activation of autophagy, a bulk protein and organelle degradation pathway. In this review, we will discuss the strategy of concerted activation of Nrf2 and autophagy as a preventive and therapeutic intervention to ameliorate ALI/ARDS.

AB - Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the clinical manifestations of severe lung damage and respiratory failure. Characterized by severe inflammation and compromised lung function, ALI/ARDS result in very high mortality of affected individuals. Currently, there are no effective treatments for ALI/ARDS, and ironically, therapies intended to aid patients (specifically mechanical ventilation, MV) may aggravate the symptoms. Key events contributing to the development of ALI/ARDS are increased oxidative and proteotoxic stresses, unresolved inflammation, and compromised alveolar-capillary barrier function. Since the airways and lung tissues are constantly exposed to gaseous oxygen and airborne toxicants, the bronchial and alveolar epithelial cells are under higher oxidative stress than other tissues. Cellular protection against oxidative stress and xenobiotics is mainly conferred by Nrf2, a transcription factor that promotes the expression of genes that regulate oxidative stress, xenobiotic metabolism and excretion, inflammation, apoptosis, autophagy, and cellular bioenergetics. Numerous studies have demonstrated the importance of Nrf2 activation in the protection against ALI/ARDS, as pharmacological activation of Nrf2 prevents the occurrence or mitigates the severity of ALI/ARDS. Another promising new therapeutic strategy in the prevention and treatment of ALI/ARDS is the activation of autophagy, a bulk protein and organelle degradation pathway. In this review, we will discuss the strategy of concerted activation of Nrf2 and autophagy as a preventive and therapeutic intervention to ameliorate ALI/ARDS.

KW - Acute lung injury

KW - Autophagy

KW - Nrf2

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85016398299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016398299&partnerID=8YFLogxK

U2 - 10.1007/s40495-016-0053-2

DO - 10.1007/s40495-016-0053-2

M3 - Review article

AN - SCOPUS:85016398299

VL - 2

SP - 91

EP - 101

JO - Current Pharmacology Reports

JF - Current Pharmacology Reports

SN - 2198-641X

IS - 2

ER -